Felodipineextended-release Tablets
NDC Package 63304-435-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Felodipineextended-release Tablets is felodipine extended-release tablets are indicated for the treatment of hypertension. Marketed by Ranbaxy Pharmaceuticals Inc, this product is identified by NDC 63304-435 and is authorized under FDA application NDA019834.

Identification & Billing

NDC Package Code
63304-435-01
Package Description
100 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
63304-435
11-Digit Billing Format
63304043501
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk
  • RxCUI: 402695 - felodipine 10 MG 24HR Extended Release Oral Tablet
  • RxCUI: 402695 - 24 HR felodipine 10 MG Extended Release Oral Tablet
  • RxCUI: 402695 - felodipine 10 MG 24 HR Extended Release Oral Tablet
  • RxCUI: 402696 - felodipine 5 MG 24HR Extended Release Oral Tablet
  • RxCUI: 402696 - 24 HR felodipine 5 MG Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Felodipineextended-release Tablets
Dosage Form
-
Usage Information
Felodipine extended-release tablets are indicated for the treatment of hypertension. Felodipine extended-release tablets may be used alone or concomitantly with other antihypertensive agents.

Regulatory & Marketing

Labeler Name
Ranbaxy Pharmaceuticals Inc
FDA Application #
NDA019834
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
09-10-2008
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 63304-435-01 identifies a specific commercial package of 100 tablet, extended release in 1 bottle of Felodipineextended-release Tablets, labeled by Ranbaxy Pharmaceuticals Inc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Ranbaxy Pharmaceuticals Inc on September 10, 2008. The current certification is valid through December 31, 2017.

How is this Ranbaxy Pharmaceuticals Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 63304043501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
63304-435-01
11-Digit CMS (5-4-2)
63304-0435-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.